XBiotech Reports Affirmative Interim Analysis of Global Phase 3 Colorectal Cancer Study (XBiotech Inc)
(WorldNews Health)

(Source: XBiotech Inc) AUSTIN, Texas, Feb. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced that an Independent Data Monitoring Committee (IDMC) has performed a prospectively planned, unblinded analysis of the Phase 3 XCITE study for the Company`s novel candidate antibody therapy for colorectal cancer. The IDMC reported that the FDA Fast-Tracked study had no safety concerns and that indications of efficacy were sufficient to recommend proceeding with the study without modification. Dr. George Fisher, Professor of Medicine, Stanford Cancer Center, and global Chair of the XCITE study, commented, `We are grateful to the IDMC members for their diligent review of the Phase...